FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:846-847 August 25, 2005 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Stallone, G. PubMed Citation

To the Editor: The regression of Kaposi's sarcoma in renal-graft recipients after switching from treatment with cyclosporine and mycophenolate mofetil to sirolimus, as reported by Stallone et al. (March 31 issue),¹ is remarkable and confirms earlier observations.^2,3 However, the immunohistochemical results in this study¹ seem to be less convincing. The detection of Flk-1/KDR was reportedly performed on "acetone-fixed kidney sections," but it is clearly stated that patients had no visceral involvement. Figure 2A, Figure 2B, and Figure 2C of the article do not seem to show greatly different vascular endothelial growth factor (VEGF) expression, certainly not in the range of . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.